Developing Active Anti-angiogenic Immunotherapies for Cancer Patients
VAXIMM is a development-stage biotech company that is primarily focused on developing active immunotherapies (vaccines) for treating cancer patients. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA to develop VXM01. VXM01 is an oral vaccine for the treatment of cancer that is unique in that it is designed to stimulate the patients' own immune system to fight the tumor vasculature, which is essential for tumors to grow beyond microscopic size. Since tumor vasculature is common to most solid cancers (e.g. lung cancer, colon cancer, breast cancer, prostate cancer, etc.), VXM01 is expected to show a broad spectrum anti-cancer activity. Also, by targeting the tumor vasculature, VXM01 avoids many of the immune evasion mechanisms and pitfalls hampering cancer vaccine approaches that target primary tumor cells directly.
VXM01 has shown tremendous anti-tumor activity in various animal studies testing different tumor types, different experimental setups, and different outcome measures. At the same time, the vaccine was remarkably well tolerated in these animals. VAXIMM is planning to initiate first clinical trials with VXM01 in 2011. In the first study it is planned to treat inoperable pancreatic cancer patients with increasing doses of VXM01. Patients will receive VXM01 on top of standard of care treatment. The study will be conducted at the University Hospital in Heidelberg, Germany.
For further information, please visit www.vaximm.com
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice